Bi-Specific MAbS Global Markets Report 2022: Catumaxomab (Removab); Blinatumomab; Duligotumab; SAR 156597 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Bi-Specific MAbS Global Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. The market is expected to reach $11.64 billion in 2026 at a CAGR of 22.7%. The global bi-specific mabs market is expected to grow from $3.80 billion in 2021 to $5.13 billion in 2022 at a compound annual growth rate … [Read more…]
